Business Context and Reporting Period
Company: Supernus Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: March 14, 2013
Reporting Period: Quarter and year ended December 31, 2012
This filing serves as a notification that the Company issued a press release regarding its financial results for the period ended December 31, 2012. The detailed results are contained in Exhibit 99.1, which is incorporated by reference.
Key Financial Metrics
The provided text is a cover document for the Form 8-K and does not contain specific numerical data regarding revenue, profit, cash flow, margins, debt, or liquidity. These figures are located in the attached press release (Exhibit 99.1), which is not included in the input text.
Material Changes
The filing text does not provide specific details on material changes versus prior periods. It references a press release containing the results but does not summarize the variances within this document.
Guidance, Outlook, and Risks
- Conference Call: The Company hosted a conference call on March 14, 2013, to review financial results and provide updates on business matters.
- Forward-Looking Statements: The filing contains forward-looking statements regarding plans, strategies, and intentions. These are subject to risks and uncertainties.
- Risk Factors: Specific risks are detailed in Item 1A of the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2012, which was expected to be filed shortly after this report.
- Legal Status: Information in Item 2.02 is "furnished" and not "filed" under the Exchange Act, limiting liability under Section 18.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific revenue, net loss, and cash position figures for Q4 and FY 2012.
- Verify the upcoming Form 10-K filing for the fiscal year ended December 31, 2012, to access audited financial statements and detailed risk factors.
- Check the archived webcast on the Company's website for management commentary on the 2012 results and 2013 outlook.
- Confirm the status of the Company's product pipeline and regulatory milestones discussed during the March 14, 2013 conference call.